NABI blood products/substitutes news

NABI said it will report a one-time charge of $1.5-$2 million ($0.04-$0.06 per share) in the third quarter ended Sept. 30, due to its voluntary withdrawal of certain lots of H-Big that were distributed prior to 1996. The immunotherapeutic is used to prevent hepatitis B transmission following accidental exposure. ...